

Ref. No.: EX/PG/PHAR/T/128G/2018,

Dated: 17/04/2018

M. Pharm. 1st Year 2nd Semester Examinations 2018.

Time: 3 hours

Subject: Pharmacology-III

Full Marks: 100

GROUP - A

(Answer any *five* questions)

1. Define neurodegenerative disorder and give some example of it. Illustrate some factors that responsible for Parkinson disease. Briefly discuss about the therapeutic management of Parkinson disease. 8+12=20
2. Write notes on- 2X10=20
 - a. Regulation of Thyroid hormone secretion.
 - b. Diabetic ketoacidosis.
3. Briefly discuss about the different methods of *in vitro* cytotoxic drug screening. 20

Ref. No.: Ex/PG/PHAR/T/128G/2018; dt 17/04/2018
Name of Examination: Master of Pharmacy 2nd Sem. Exam. 2018
Subject: PHARMACOLOGY III

Time: 3 hrs

Full Marks:100

GROUP - B

Q4) Explain critically the following:

- a) Vasodilator Dipyridamol can't be used in place of Nitrates. -----(4)
- b) Why Ramipril and not Olmesartan can be used for management of Nitrate tolerance----- (5)
- c) Nitrate mediated vasodilatation do not reduce Blood Pressure. -----(5)
- d) Initial use of β -Blockers some time precipitate bronchospasm (Explain with cAMP) and coronary resistance. -----(6)

Q5) Explain whether cardio-specific or non-specific β -Blockers are more suitable for CHF?----- (6)

Why Obesity is related with chronic use of β -Blockers? ----- (2)

Explain the hypothesis where RAA and Free Radicals are believed to be responsible for Nitrate tolerance ----- (7)

Explain why short acting DHP (Nifedipine) although is able to relieve severe hypertension and terminate attacks of coronary spasms--- presents with serious adverse effects? ----- (5)

Q6) (a) How β -Blockers can be used for cardiac remodeling? ----- (8)

(b) Explain why Atenolol is not suitable for acute- management of hypertension and (c) Nitrates are often considered as better Veno-dilators? ----- (6+6)